Gastric

Gastric bypass diet: What to eat after the surgeryThe gastric bypass diet outlines what you can eat and how much after gastric bypass surgery.By Mayo Clinic StaffDefinition A post-bariatric surgery diet helps people who are…

Anti-HER2 and Anti-HER3 monoclonal antibodies designed to have a high drug-to-antibody ratio intended enhance the bystander killing effect and be effective against a number of epithelial tumors Antibody CDRs against HER2 and HER3…

<!-- Name:DistributionId Value:8801461 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4570 -->…

A newly developed test could help doctors more accurately predict whether individuals who undergo gastric bypass surgery will experience a remission of type 2 diabetes within two years of the procedure, according to University of Utah…

Researchers at the University of Arizona Health Sciences are hoping to catch stomach cancer before it develops in at-risk patients. In a paper published in Gastroenterology, researchers identified a genetic variation that could help…

When the bacterium Helicobacter pylori infects the stomach, it causes gastric inflammation and increases the risk of stomach cancer. A team of researchers from Charité -- Universitätsmedizin Berlin and the Max Delbrück Center for Molecular…

New clinical trial supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ., USA for Phase 2 clinical study (nextHERIZON) in HER-2 positive gastric or gastroesophageal junction adenocarcinomasnextHERIZON will assess…

CYNK-101 is an investigational genetically modified NK cell therapy designed to synergize with antibody therapeutics for difficult to treat cancers of high unmet medical need Phase 1/2a clinical trial will evaluate the safety and…

A study by researchers at Mayo Clinic Cancer Center in Florida is validating the use of genomic sequencing to predict the likelihood that patients with gastric cancer will derive benefit from chemotherapy or from immunotherapy. The study is…

SOUTH SAN FRANCISCO, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today…